nodes	percent_of_prediction	percent_of_DWPC	metapath
Magnesium salicylate—PTGS2—thyroid cancer	0.77	1	CbGaD
Magnesium salicylate—ALB—Vandetanib—thyroid cancer	0.106	1	CbGbCtD
Magnesium salicylate—PTGS1—Eicosanoid Synthesis—PTGES2—thyroid cancer	0.00619	0.138	CbGpPWpGaD
Magnesium salicylate—PTGS2—Eicosanoid Synthesis—PTGES2—thyroid cancer	0.00492	0.11	CbGpPWpGaD
Magnesium salicylate—PTGS1—Synthesis of Prostaglandins (PG) and Thromboxanes (TX)—HPGD—thyroid cancer	0.00465	0.104	CbGpPWpGaD
Magnesium salicylate—PTGS2—Synthesis of Prostaglandins (PG) and Thromboxanes (TX)—HPGD—thyroid cancer	0.0037	0.0824	CbGpPWpGaD
Magnesium salicylate—Hypocalcaemia—Vandetanib—thyroid cancer	0.00293	0.0413	CcSEcCtD
Magnesium salicylate—Depressed level of consciousness—Vandetanib—thyroid cancer	0.00259	0.0365	CcSEcCtD
Magnesium salicylate—PTGS1—Prostaglandin Synthesis and Regulation—HPGD—thyroid cancer	0.00253	0.0564	CbGpPWpGaD
Magnesium salicylate—PTGS2—Signaling mediated by p38-alpha and p38-beta—KRT19—thyroid cancer	0.0022	0.0491	CbGpPWpGaD
Magnesium salicylate—PTGS2—Prostaglandin Synthesis and Regulation—HPGD—thyroid cancer	0.00201	0.0448	CbGpPWpGaD
Magnesium salicylate—Lethargy—Vandetanib—thyroid cancer	0.00199	0.028	CcSEcCtD
Magnesium salicylate—Hypocalcaemia—Sorafenib—thyroid cancer	0.00198	0.0278	CcSEcCtD
Magnesium salicylate—Trisalicylate-choline—PTGS2—thyroid cancer	0.00191	0.24	CrCbGaD
Magnesium salicylate—Olsalazine—PPARG—thyroid cancer	0.00188	0.236	CrCbGaD
Magnesium salicylate—Skin exfoliation—Sorafenib—thyroid cancer	0.00173	0.0243	CcSEcCtD
Magnesium salicylate—PTGS1—Arachidonic acid metabolism—HPGD—thyroid cancer	0.00168	0.0375	CbGpPWpGaD
Magnesium salicylate—Epistaxis—Vandetanib—thyroid cancer	0.00142	0.0199	CcSEcCtD
Magnesium salicylate—PTGS2—Arachidonic acid metabolism—HPGD—thyroid cancer	0.00133	0.0298	CbGpPWpGaD
Magnesium salicylate—PTGS2—Aryl Hydrocarbon Receptor—RET—thyroid cancer	0.0013	0.0291	CbGpPWpGaD
Magnesium salicylate—Erythema multiforme—Vandetanib—thyroid cancer	0.00127	0.0179	CcSEcCtD
Magnesium salicylate—Abdominal pain upper—Sorafenib—thyroid cancer	0.0012	0.0169	CcSEcCtD
Magnesium salicylate—Body temperature decreased—Epirubicin—thyroid cancer	0.00119	0.0168	CcSEcCtD
Magnesium salicylate—Hypothermia—Epirubicin—thyroid cancer	0.00119	0.0168	CcSEcCtD
Magnesium salicylate—Salicylate-sodium—PTGS2—thyroid cancer	0.00116	0.145	CrCbGaD
Magnesium salicylate—Gastric ulcer—Epirubicin—thyroid cancer	0.00115	0.0162	CcSEcCtD
Magnesium salicylate—Dysgeusia—Vandetanib—thyroid cancer	0.00115	0.0162	CcSEcCtD
Magnesium salicylate—Body temperature decreased—Doxorubicin—thyroid cancer	0.0011	0.0155	CcSEcCtD
Magnesium salicylate—Hypothermia—Doxorubicin—thyroid cancer	0.0011	0.0155	CcSEcCtD
Magnesium salicylate—Abdominal discomfort—Sorafenib—thyroid cancer	0.00109	0.0153	CcSEcCtD
Magnesium salicylate—ALB—FOXA2 and FOXA3 transcription factor networks—NKX2-1—thyroid cancer	0.00107	0.0238	CbGpPWpGaD
Magnesium salicylate—Gastric ulcer—Doxorubicin—thyroid cancer	0.00107	0.015	CcSEcCtD
Magnesium salicylate—ALB—Recycling of bile acids and salts—RXRA—thyroid cancer	0.000971	0.0216	CbGpPWpGaD
Magnesium salicylate—Burning sensation—Epirubicin—thyroid cancer	0.000963	0.0136	CcSEcCtD
Magnesium salicylate—Oedema—Vandetanib—thyroid cancer	0.000958	0.0135	CcSEcCtD
Magnesium salicylate—Epistaxis—Sorafenib—thyroid cancer	0.000955	0.0134	CcSEcCtD
Magnesium salicylate—Burning sensation—Doxorubicin—thyroid cancer	0.000891	0.0125	CcSEcCtD
Magnesium salicylate—Erythema multiforme—Sorafenib—thyroid cancer	0.00086	0.0121	CcSEcCtD
Magnesium salicylate—Tinnitus—Sorafenib—thyroid cancer	0.000848	0.0119	CcSEcCtD
Magnesium salicylate—Flushing—Sorafenib—thyroid cancer	0.000844	0.0119	CcSEcCtD
Magnesium salicylate—Dyspepsia—Vandetanib—thyroid cancer	0.000843	0.0119	CcSEcCtD
Magnesium salicylate—PTGS1—Synthesis of Prostaglandins (PG) and Thromboxanes (TX)—PTGS2—thyroid cancer	0.000835	0.0186	CbGpPWpGaD
Magnesium salicylate—Decreased appetite—Vandetanib—thyroid cancer	0.000833	0.0117	CcSEcCtD
Magnesium salicylate—Stinging—Epirubicin—thyroid cancer	0.000826	0.0116	CcSEcCtD
Magnesium salicylate—Pain—Vandetanib—thyroid cancer	0.000819	0.0115	CcSEcCtD
Magnesium salicylate—Constipation—Vandetanib—thyroid cancer	0.000819	0.0115	CcSEcCtD
Magnesium salicylate—Nepafenac—PTGS2—thyroid cancer	0.000812	0.102	CrCbGaD
Magnesium salicylate—Olsalazine—PTGS2—thyroid cancer	0.000794	0.0995	CrCbGaD
Magnesium salicylate—Erythema—Sorafenib—thyroid cancer	0.000792	0.0111	CcSEcCtD
Magnesium salicylate—Dysgeusia—Sorafenib—thyroid cancer	0.000775	0.0109	CcSEcCtD
Magnesium salicylate—Stinging—Doxorubicin—thyroid cancer	0.000764	0.0108	CcSEcCtD
Magnesium salicylate—Hypocalcaemia—Epirubicin—thyroid cancer	0.000731	0.0103	CcSEcCtD
Magnesium salicylate—Pruritus—Vandetanib—thyroid cancer	0.000678	0.00954	CcSEcCtD
Magnesium salicylate—Hypocalcaemia—Doxorubicin—thyroid cancer	0.000676	0.00952	CcSEcCtD
Magnesium salicylate—Salsalate—PTGS2—thyroid cancer	0.000675	0.0846	CrCbGaD
Magnesium salicylate—Diarrhoea—Vandetanib—thyroid cancer	0.000655	0.00922	CcSEcCtD
Magnesium salicylate—PTGS1—Overview of nanoparticle effects—PTGS2—thyroid cancer	0.000654	0.0146	CbGpPWpGaD
Magnesium salicylate—Skin exfoliation—Epirubicin—thyroid cancer	0.000639	0.00899	CcSEcCtD
Magnesium salicylate—Shock—Sorafenib—thyroid cancer	0.000636	0.00895	CcSEcCtD
Magnesium salicylate—Dizziness—Vandetanib—thyroid cancer	0.000633	0.00891	CcSEcCtD
Magnesium salicylate—Anorexia—Sorafenib—thyroid cancer	0.000616	0.00867	CcSEcCtD
Magnesium salicylate—Oesophagitis—Epirubicin—thyroid cancer	0.000612	0.00861	CcSEcCtD
Magnesium salicylate—Vomiting—Vandetanib—thyroid cancer	0.000609	0.00857	CcSEcCtD
Magnesium salicylate—Ecchymosis—Epirubicin—thyroid cancer	0.000605	0.00852	CcSEcCtD
Magnesium salicylate—Rash—Vandetanib—thyroid cancer	0.000604	0.0085	CcSEcCtD
Magnesium salicylate—Dermatitis—Vandetanib—thyroid cancer	0.000603	0.00849	CcSEcCtD
Magnesium salicylate—Headache—Vandetanib—thyroid cancer	0.0006	0.00844	CcSEcCtD
Magnesium salicylate—Skin exfoliation—Doxorubicin—thyroid cancer	0.000591	0.00832	CcSEcCtD
Magnesium salicylate—Nausea—Vandetanib—thyroid cancer	0.000569	0.00801	CcSEcCtD
Magnesium salicylate—Dyspepsia—Sorafenib—thyroid cancer	0.000569	0.008	CcSEcCtD
Magnesium salicylate—Oesophagitis—Doxorubicin—thyroid cancer	0.000566	0.00796	CcSEcCtD
Magnesium salicylate—Decreased appetite—Sorafenib—thyroid cancer	0.000562	0.0079	CcSEcCtD
Magnesium salicylate—Ecchymosis—Doxorubicin—thyroid cancer	0.00056	0.00788	CcSEcCtD
Magnesium salicylate—Pain—Sorafenib—thyroid cancer	0.000552	0.00778	CcSEcCtD
Magnesium salicylate—Constipation—Sorafenib—thyroid cancer	0.000552	0.00778	CcSEcCtD
Magnesium salicylate—PTGS1—Eicosanoid Synthesis—PTGS2—thyroid cancer	0.000543	0.0121	CbGpPWpGaD
Magnesium salicylate—Urticaria—Sorafenib—thyroid cancer	0.000513	0.00722	CcSEcCtD
Magnesium salicylate—ALB—Bile acid and bile salt metabolism—RXRA—thyroid cancer	0.000507	0.0113	CbGpPWpGaD
Magnesium salicylate—Lethargy—Epirubicin—thyroid cancer	0.000496	0.00698	CcSEcCtD
Magnesium salicylate—Lethargy—Doxorubicin—thyroid cancer	0.000459	0.00646	CcSEcCtD
Magnesium salicylate—Pruritus—Sorafenib—thyroid cancer	0.000457	0.00643	CcSEcCtD
Magnesium salicylate—PTGS1—Prostaglandin Synthesis and Regulation—PTGS2—thyroid cancer	0.000454	0.0101	CbGpPWpGaD
Magnesium salicylate—Abdominal pain upper—Epirubicin—thyroid cancer	0.000444	0.00624	CcSEcCtD
Magnesium salicylate—Diarrhoea—Sorafenib—thyroid cancer	0.000442	0.00622	CcSEcCtD
Magnesium salicylate—Dizziness—Sorafenib—thyroid cancer	0.000427	0.00601	CcSEcCtD
Magnesium salicylate—PTGS1—Phase 1 - Functionalization of compounds—RXRA—thyroid cancer	0.000426	0.00949	CbGpPWpGaD
Magnesium salicylate—Asthma—Epirubicin—thyroid cancer	0.00042	0.00591	CcSEcCtD
Magnesium salicylate—Salicylic acid—PTGS2—thyroid cancer	0.000415	0.0521	CrCbGaD
Magnesium salicylate—Vomiting—Sorafenib—thyroid cancer	0.000411	0.00578	CcSEcCtD
Magnesium salicylate—Abdominal pain upper—Doxorubicin—thyroid cancer	0.000411	0.00578	CcSEcCtD
Magnesium salicylate—Rash—Sorafenib—thyroid cancer	0.000407	0.00573	CcSEcCtD
Magnesium salicylate—Dermatitis—Sorafenib—thyroid cancer	0.000407	0.00573	CcSEcCtD
Magnesium salicylate—Headache—Sorafenib—thyroid cancer	0.000405	0.0057	CcSEcCtD
Magnesium salicylate—Asthma—Doxorubicin—thyroid cancer	0.000388	0.00547	CcSEcCtD
Magnesium salicylate—Nausea—Sorafenib—thyroid cancer	0.000384	0.0054	CcSEcCtD
Magnesium salicylate—PTGS2—Spinal Cord Injury—LGALS3—thyroid cancer	0.000382	0.00853	CbGpPWpGaD
Magnesium salicylate—Weight increased—Epirubicin—thyroid cancer	0.000382	0.00538	CcSEcCtD
Magnesium salicylate—Drowsiness—Epirubicin—thyroid cancer	0.000374	0.00527	CcSEcCtD
Magnesium salicylate—Sweating—Epirubicin—thyroid cancer	0.000359	0.00505	CcSEcCtD
Magnesium salicylate—Weight increased—Doxorubicin—thyroid cancer	0.000354	0.00498	CcSEcCtD
Magnesium salicylate—Epistaxis—Epirubicin—thyroid cancer	0.000353	0.00497	CcSEcCtD
Magnesium salicylate—Drowsiness—Doxorubicin—thyroid cancer	0.000346	0.00488	CcSEcCtD
Magnesium salicylate—Hepatitis—Epirubicin—thyroid cancer	0.000336	0.00473	CcSEcCtD
Magnesium salicylate—Sweating—Doxorubicin—thyroid cancer	0.000332	0.00467	CcSEcCtD
Magnesium salicylate—Ketoprofen—PTGS2—thyroid cancer	0.000329	0.0413	CrCbGaD
Magnesium salicylate—Epistaxis—Doxorubicin—thyroid cancer	0.000327	0.0046	CcSEcCtD
Magnesium salicylate—Erythema multiforme—Epirubicin—thyroid cancer	0.000318	0.00447	CcSEcCtD
Magnesium salicylate—Tinnitus—Epirubicin—thyroid cancer	0.000313	0.00441	CcSEcCtD
Magnesium salicylate—Flushing—Epirubicin—thyroid cancer	0.000312	0.00439	CcSEcCtD
Magnesium salicylate—Hepatitis—Doxorubicin—thyroid cancer	0.000311	0.00438	CcSEcCtD
Magnesium salicylate—PTGS2—Calcineurin-regulated NFAT-dependent transcription in lymphocytes—PPARG—thyroid cancer	0.000304	0.00679	CbGpPWpGaD
Magnesium salicylate—PTGS1—Arachidonic acid metabolism—PTGS2—thyroid cancer	0.000302	0.00673	CbGpPWpGaD
Magnesium salicylate—Erythema multiforme—Doxorubicin—thyroid cancer	0.000294	0.00414	CcSEcCtD
Magnesium salicylate—Erythema—Epirubicin—thyroid cancer	0.000293	0.00412	CcSEcCtD
Magnesium salicylate—Tinnitus—Doxorubicin—thyroid cancer	0.00029	0.00408	CcSEcCtD
Magnesium salicylate—Flushing—Doxorubicin—thyroid cancer	0.000289	0.00406	CcSEcCtD
Magnesium salicylate—Dysgeusia—Epirubicin—thyroid cancer	0.000286	0.00403	CcSEcCtD
Magnesium salicylate—Erythema—Doxorubicin—thyroid cancer	0.000271	0.00381	CcSEcCtD
Magnesium salicylate—Dysgeusia—Doxorubicin—thyroid cancer	0.000265	0.00373	CcSEcCtD
Magnesium salicylate—PTGS2—Spinal Cord Injury—CDK1—thyroid cancer	0.000261	0.00583	CbGpPWpGaD
Magnesium salicylate—Confusional state—Epirubicin—thyroid cancer	0.000241	0.00339	CcSEcCtD
Magnesium salicylate—PTGS1—Metabolism of lipids and lipoproteins—HPGD—thyroid cancer	0.00024	0.00536	CbGpPWpGaD
Magnesium salicylate—Oedema—Epirubicin—thyroid cancer	0.000239	0.00336	CcSEcCtD
Magnesium salicylate—Shock—Epirubicin—thyroid cancer	0.000235	0.00331	CcSEcCtD
Magnesium salicylate—Hyperhidrosis—Epirubicin—thyroid cancer	0.000231	0.00325	CcSEcCtD
Magnesium salicylate—Anorexia—Epirubicin—thyroid cancer	0.000228	0.0032	CcSEcCtD
Magnesium salicylate—PTGS1—Biological oxidations—RXRA—thyroid cancer	0.000226	0.00504	CbGpPWpGaD
Magnesium salicylate—Hypotension—Epirubicin—thyroid cancer	0.000223	0.00314	CcSEcCtD
Magnesium salicylate—Confusional state—Doxorubicin—thyroid cancer	0.000223	0.00314	CcSEcCtD
Magnesium salicylate—Oedema—Doxorubicin—thyroid cancer	0.000221	0.00311	CcSEcCtD
Magnesium salicylate—Shock—Doxorubicin—thyroid cancer	0.000217	0.00306	CcSEcCtD
Magnesium salicylate—Hyperhidrosis—Doxorubicin—thyroid cancer	0.000214	0.00301	CcSEcCtD
Magnesium salicylate—Somnolence—Epirubicin—thyroid cancer	0.000212	0.00299	CcSEcCtD
Magnesium salicylate—Anorexia—Doxorubicin—thyroid cancer	0.000211	0.00296	CcSEcCtD
Magnesium salicylate—Dyspepsia—Epirubicin—thyroid cancer	0.00021	0.00296	CcSEcCtD
Magnesium salicylate—Decreased appetite—Epirubicin—thyroid cancer	0.000208	0.00292	CcSEcCtD
Magnesium salicylate—Hypotension—Doxorubicin—thyroid cancer	0.000206	0.00291	CcSEcCtD
Magnesium salicylate—Pain—Epirubicin—thyroid cancer	0.000204	0.00287	CcSEcCtD
Magnesium salicylate—Constipation—Epirubicin—thyroid cancer	0.000204	0.00287	CcSEcCtD
Magnesium salicylate—PTGS2—Aryl Hydrocarbon Receptor—NRAS—thyroid cancer	0.000199	0.00444	CbGpPWpGaD
Magnesium salicylate—Feeling abnormal—Epirubicin—thyroid cancer	0.000197	0.00277	CcSEcCtD
Magnesium salicylate—Somnolence—Doxorubicin—thyroid cancer	0.000196	0.00276	CcSEcCtD
Magnesium salicylate—Dyspepsia—Doxorubicin—thyroid cancer	0.000194	0.00274	CcSEcCtD
Magnesium salicylate—Decreased appetite—Doxorubicin—thyroid cancer	0.000192	0.0027	CcSEcCtD
Magnesium salicylate—PTGS1—Selenium Micronutrient Network—PTGS2—thyroid cancer	0.000192	0.00428	CbGpPWpGaD
Magnesium salicylate—PTGS2—Metabolism of lipids and lipoproteins—HPGD—thyroid cancer	0.000191	0.00425	CbGpPWpGaD
Magnesium salicylate—Urticaria—Epirubicin—thyroid cancer	0.00019	0.00267	CcSEcCtD
Magnesium salicylate—PTGS2—Signaling mediated by p38-alpha and p38-beta—TP53—thyroid cancer	0.00019	0.00423	CbGpPWpGaD
Magnesium salicylate—Constipation—Doxorubicin—thyroid cancer	0.000189	0.00266	CcSEcCtD
Magnesium salicylate—Pain—Doxorubicin—thyroid cancer	0.000189	0.00266	CcSEcCtD
Magnesium salicylate—Feeling abnormal—Doxorubicin—thyroid cancer	0.000182	0.00256	CcSEcCtD
Magnesium salicylate—Urticaria—Doxorubicin—thyroid cancer	0.000176	0.00247	CcSEcCtD
Magnesium salicylate—PTGS2—Aryl Hydrocarbon Receptor—KRAS—thyroid cancer	0.000171	0.00382	CbGpPWpGaD
Magnesium salicylate—Pruritus—Epirubicin—thyroid cancer	0.000169	0.00238	CcSEcCtD
Magnesium salicylate—PTGS1—Metabolism—MINPP1—thyroid cancer	0.000166	0.0037	CbGpPWpGaD
Magnesium salicylate—ALB—SLC-mediated transmembrane transport—CP—thyroid cancer	0.000166	0.0037	CbGpPWpGaD
Magnesium salicylate—ALB—SLC-mediated transmembrane transport—TPR—thyroid cancer	0.000166	0.0037	CbGpPWpGaD
Magnesium salicylate—PTGS2—Integrated Pancreatic Cancer Pathway—RXRA—thyroid cancer	0.000165	0.00368	CbGpPWpGaD
Magnesium salicylate—Diarrhoea—Epirubicin—thyroid cancer	0.000163	0.0023	CcSEcCtD
Magnesium salicylate—Dizziness—Epirubicin—thyroid cancer	0.000158	0.00222	CcSEcCtD
Magnesium salicylate—Pruritus—Doxorubicin—thyroid cancer	0.000156	0.0022	CcSEcCtD
Magnesium salicylate—ALB—Metabolism of lipids and lipoproteins—HPGD—thyroid cancer	0.000154	0.00344	CbGpPWpGaD
Magnesium salicylate—Vomiting—Epirubicin—thyroid cancer	0.000152	0.00214	CcSEcCtD
Magnesium salicylate—Diarrhoea—Doxorubicin—thyroid cancer	0.000151	0.00213	CcSEcCtD
Magnesium salicylate—Rash—Epirubicin—thyroid cancer	0.000151	0.00212	CcSEcCtD
Magnesium salicylate—Dermatitis—Epirubicin—thyroid cancer	0.00015	0.00212	CcSEcCtD
Magnesium salicylate—Headache—Epirubicin—thyroid cancer	0.00015	0.00211	CcSEcCtD
Magnesium salicylate—Dizziness—Doxorubicin—thyroid cancer	0.000146	0.00206	CcSEcCtD
Magnesium salicylate—PTGS2—Aryl Hydrocarbon Receptor—HRAS—thyroid cancer	0.000146	0.00325	CbGpPWpGaD
Magnesium salicylate—PTGS2—C-MYB transcription factor network—CCND1—thyroid cancer	0.000143	0.00319	CbGpPWpGaD
Magnesium salicylate—Nausea—Epirubicin—thyroid cancer	0.000142	0.002	CcSEcCtD
Magnesium salicylate—PTGS1—Metabolism—NDUFA13—thyroid cancer	0.000141	0.00315	CbGpPWpGaD
Magnesium salicylate—Vomiting—Doxorubicin—thyroid cancer	0.00014	0.00198	CcSEcCtD
Magnesium salicylate—Rash—Doxorubicin—thyroid cancer	0.000139	0.00196	CcSEcCtD
Magnesium salicylate—Dermatitis—Doxorubicin—thyroid cancer	0.000139	0.00196	CcSEcCtD
Magnesium salicylate—Headache—Doxorubicin—thyroid cancer	0.000138	0.00195	CcSEcCtD
Magnesium salicylate—PTGS2—Disease—TRIM24—thyroid cancer	0.000134	0.00298	CbGpPWpGaD
Magnesium salicylate—PTGS1—Metabolism—CHST14—thyroid cancer	0.000133	0.00296	CbGpPWpGaD
Magnesium salicylate—PTGS2—Metabolism—MINPP1—thyroid cancer	0.000132	0.00294	CbGpPWpGaD
Magnesium salicylate—Nausea—Doxorubicin—thyroid cancer	0.000131	0.00185	CcSEcCtD
Magnesium salicylate—PTGS2—Disease—CHST14—thyroid cancer	0.000126	0.00281	CbGpPWpGaD
Magnesium salicylate—ALB—SLC-mediated transmembrane transport—SLC5A5—thyroid cancer	0.000124	0.00277	CbGpPWpGaD
Magnesium salicylate—ALB—Selenium Micronutrient Network—PTGS2—thyroid cancer	0.000123	0.00275	CbGpPWpGaD
Magnesium salicylate—PTGS2—C-MYB transcription factor network—NRAS—thyroid cancer	0.000123	0.00274	CbGpPWpGaD
Magnesium salicylate—PTGS2—Disease—TRIM33—thyroid cancer	0.000119	0.00266	CbGpPWpGaD
Magnesium salicylate—PTGS2—Metabolism—NDUFA13—thyroid cancer	0.000112	0.0025	CbGpPWpGaD
Magnesium salicylate—PTGS2—Spinal Cord Injury—CCND1—thyroid cancer	0.000109	0.00243	CbGpPWpGaD
Magnesium salicylate—ALB—FOXA2 and FOXA3 transcription factor networks—AKT1—thyroid cancer	0.000108	0.00241	CbGpPWpGaD
Magnesium salicylate—PTGS1—Metabolism—HPGD—thyroid cancer	0.000107	0.00239	CbGpPWpGaD
Magnesium salicylate—ALB—Metabolism—MINPP1—thyroid cancer	0.000107	0.00238	CbGpPWpGaD
Magnesium salicylate—PTGS2—C-MYB transcription factor network—KRAS—thyroid cancer	0.000106	0.00236	CbGpPWpGaD
Magnesium salicylate—PTGS2—Metabolism—CHST14—thyroid cancer	0.000105	0.00235	CbGpPWpGaD
Magnesium salicylate—ALB—Hemostasis—PRKAR1A—thyroid cancer	9.58e-05	0.00214	CbGpPWpGaD
Magnesium salicylate—ALB—Folate Metabolism—TP53—thyroid cancer	9.23e-05	0.00206	CbGpPWpGaD
Magnesium salicylate—ALB—Metabolism—NDUFA13—thyroid cancer	9.07e-05	0.00202	CbGpPWpGaD
Magnesium salicylate—PTGS2—C-MYB transcription factor network—HRAS—thyroid cancer	9e-05	0.00201	CbGpPWpGaD
Magnesium salicylate—PTGS1—Metabolism of lipids and lipoproteins—RXRA—thyroid cancer	8.68e-05	0.00194	CbGpPWpGaD
Magnesium salicylate—ALB—Metabolism—CHST14—thyroid cancer	8.53e-05	0.0019	CbGpPWpGaD
Magnesium salicylate—PTGS2—Metabolism—HPGD—thyroid cancer	8.49e-05	0.00189	CbGpPWpGaD
Magnesium salicylate—ALB—Transmembrane transport of small molecules—TPR—thyroid cancer	8.43e-05	0.00188	CbGpPWpGaD
Magnesium salicylate—ALB—Transmembrane transport of small molecules—CP—thyroid cancer	8.43e-05	0.00188	CbGpPWpGaD
Magnesium salicylate—ALB—Transmembrane transport of small molecules—PRKAR1A—thyroid cancer	8.29e-05	0.00185	CbGpPWpGaD
Magnesium salicylate—PTGS2—Disease—TCF7L1—thyroid cancer	7.96e-05	0.00178	CbGpPWpGaD
Magnesium salicylate—PTGS2—Integrated Pancreatic Cancer Pathway—CCND1—thyroid cancer	7.41e-05	0.00165	CbGpPWpGaD
Magnesium salicylate—PTGS2—Spinal Cord Injury—TP53—thyroid cancer	7.17e-05	0.0016	CbGpPWpGaD
Magnesium salicylate—PTGS2—Integrated Pancreatic Cancer Pathway—PTEN—thyroid cancer	7.15e-05	0.00159	CbGpPWpGaD
Magnesium salicylate—PTGS2—Metabolism of lipids and lipoproteins—RXRA—thyroid cancer	6.89e-05	0.00154	CbGpPWpGaD
Magnesium salicylate—ALB—Metabolism—HPGD—thyroid cancer	6.87e-05	0.00153	CbGpPWpGaD
Magnesium salicylate—ALB—Hemostasis—IFNA2—thyroid cancer	6.34e-05	0.00141	CbGpPWpGaD
Magnesium salicylate—ALB—Transmembrane transport of small molecules—SLC5A5—thyroid cancer	6.31e-05	0.00141	CbGpPWpGaD
Magnesium salicylate—PTGS1—Metabolism—TPR—thyroid cancer	6.15e-05	0.00137	CbGpPWpGaD
Magnesium salicylate—PTGS1—Metabolism—PRKAR1A—thyroid cancer	6.05e-05	0.00135	CbGpPWpGaD
Magnesium salicylate—PTGS2—Disease—TPR—thyroid cancer	5.83e-05	0.0013	CbGpPWpGaD
Magnesium salicylate—PTGS2—Disease—PRKAR1A—thyroid cancer	5.73e-05	0.00128	CbGpPWpGaD
Magnesium salicylate—ALB—Metabolism of lipids and lipoproteins—RXRA—thyroid cancer	5.57e-05	0.00124	CbGpPWpGaD
Magnesium salicylate—PTGS2—Integrated Pancreatic Cancer Pathway—KRAS—thyroid cancer	5.49e-05	0.00122	CbGpPWpGaD
Magnesium salicylate—PTGS1—Metabolism of lipids and lipoproteins—PPARG—thyroid cancer	5.48e-05	0.00122	CbGpPWpGaD
Magnesium salicylate—PTGS2—Disease—MEN1—thyroid cancer	5.48e-05	0.00122	CbGpPWpGaD
Magnesium salicylate—ALB—Transmembrane transport of small molecules—RXRA—thyroid cancer	5.3e-05	0.00118	CbGpPWpGaD
Magnesium salicylate—PTGS2—Metabolism—TPR—thyroid cancer	4.88e-05	0.00109	CbGpPWpGaD
Magnesium salicylate—PTGS2—Integrated Pancreatic Cancer Pathway—TP53—thyroid cancer	4.88e-05	0.00109	CbGpPWpGaD
Magnesium salicylate—PTGS2—Metabolism—PRKAR1A—thyroid cancer	4.8e-05	0.00107	CbGpPWpGaD
Magnesium salicylate—PTGS1—Metabolism—SLC5A5—thyroid cancer	4.6e-05	0.00103	CbGpPWpGaD
Magnesium salicylate—PTGS2—Disease—CALCA—thyroid cancer	4.36e-05	0.000973	CbGpPWpGaD
Magnesium salicylate—PTGS2—Metabolism of lipids and lipoproteins—PPARG—thyroid cancer	4.35e-05	0.00097	CbGpPWpGaD
Magnesium salicylate—PTGS1—Metabolism of lipids and lipoproteins—PTGS2—thyroid cancer	4.31e-05	0.000961	CbGpPWpGaD
Magnesium salicylate—PTGS2—Integrated Pancreatic Cancer Pathway—AKT1—thyroid cancer	4.12e-05	0.000919	CbGpPWpGaD
Magnesium salicylate—PTGS2—Disease—CDK1—thyroid cancer	3.95e-05	0.00088	CbGpPWpGaD
Magnesium salicylate—ALB—Metabolism—TPR—thyroid cancer	3.95e-05	0.00088	CbGpPWpGaD
Magnesium salicylate—ALB—Metabolism—PRKAR1A—thyroid cancer	3.88e-05	0.000866	CbGpPWpGaD
Magnesium salicylate—PTGS1—Metabolism—RXRA—thyroid cancer	3.87e-05	0.000862	CbGpPWpGaD
Magnesium salicylate—PTGS1—Metabolism of lipids and lipoproteins—PTEN—thyroid cancer	3.76e-05	0.000838	CbGpPWpGaD
Magnesium salicylate—PTGS2—Metabolism—SLC5A5—thyroid cancer	3.65e-05	0.000815	CbGpPWpGaD
Magnesium salicylate—ALB—Metabolism of lipids and lipoproteins—PPARG—thyroid cancer	3.52e-05	0.000785	CbGpPWpGaD
Magnesium salicylate—PTGS2—Disease—NRG1—thyroid cancer	3.17e-05	0.000707	CbGpPWpGaD
Magnesium salicylate—PTGS2—Metabolism—RXRA—thyroid cancer	3.07e-05	0.000684	CbGpPWpGaD
Magnesium salicylate—PTGS2—Metabolism of lipids and lipoproteins—PTEN—thyroid cancer	2.98e-05	0.000666	CbGpPWpGaD
Magnesium salicylate—ALB—Platelet activation, signaling and aggregation—AKT1—thyroid cancer	2.97e-05	0.000661	CbGpPWpGaD
Magnesium salicylate—ALB—Metabolism—SLC5A5—thyroid cancer	2.95e-05	0.000659	CbGpPWpGaD
Magnesium salicylate—PTGS2—Disease—TERT—thyroid cancer	2.85e-05	0.000635	CbGpPWpGaD
Magnesium salicylate—ALB—Metabolism of lipids and lipoproteins—PTGS2—thyroid cancer	2.77e-05	0.000618	CbGpPWpGaD
Magnesium salicylate—PTGS2—Disease—HIF1A—thyroid cancer	2.72e-05	0.000607	CbGpPWpGaD
Magnesium salicylate—ALB—Metabolism—RXRA—thyroid cancer	2.48e-05	0.000554	CbGpPWpGaD
Magnesium salicylate—PTGS1—Metabolism—PPARG—thyroid cancer	2.44e-05	0.000544	CbGpPWpGaD
Magnesium salicylate—ALB—Metabolism of lipids and lipoproteins—PTEN—thyroid cancer	2.41e-05	0.000539	CbGpPWpGaD
Magnesium salicylate—ALB—Hemostasis—NRAS—thyroid cancer	2.37e-05	0.000528	CbGpPWpGaD
Magnesium salicylate—PTGS2—Disease—BRAF—thyroid cancer	2.25e-05	0.000502	CbGpPWpGaD
Magnesium salicylate—ALB—Hemostasis—KRAS—thyroid cancer	2.04e-05	0.000454	CbGpPWpGaD
Magnesium salicylate—PTGS2—Metabolism—PPARG—thyroid cancer	1.94e-05	0.000432	CbGpPWpGaD
Magnesium salicylate—PTGS1—Metabolism—PTGS2—thyroid cancer	1.92e-05	0.000428	CbGpPWpGaD
Magnesium salicylate—ALB—Hemostasis—TP53—thyroid cancer	1.81e-05	0.000404	CbGpPWpGaD
Magnesium salicylate—ALB—Hemostasis—HRAS—thyroid cancer	1.73e-05	0.000386	CbGpPWpGaD
Magnesium salicylate—PTGS1—Metabolism—PTEN—thyroid cancer	1.67e-05	0.000373	CbGpPWpGaD
Magnesium salicylate—PTGS2—Disease—PTEN—thyroid cancer	1.59e-05	0.000354	CbGpPWpGaD
Magnesium salicylate—ALB—Metabolism—PPARG—thyroid cancer	1.57e-05	0.00035	CbGpPWpGaD
Magnesium salicylate—ALB—Hemostasis—AKT1—thyroid cancer	1.53e-05	0.000341	CbGpPWpGaD
Magnesium salicylate—PTGS2—Disease—NRAS—thyroid cancer	1.42e-05	0.000316	CbGpPWpGaD
Magnesium salicylate—PTGS2—Metabolism—PTEN—thyroid cancer	1.33e-05	0.000296	CbGpPWpGaD
Magnesium salicylate—ALB—Metabolism—PTGS2—thyroid cancer	1.23e-05	0.000275	CbGpPWpGaD
Magnesium salicylate—PTGS2—Disease—KRAS—thyroid cancer	1.22e-05	0.000272	CbGpPWpGaD
Magnesium salicylate—ALB—Metabolism—PTEN—thyroid cancer	1.08e-05	0.00024	CbGpPWpGaD
Magnesium salicylate—PTGS2—Disease—HRAS—thyroid cancer	1.04e-05	0.000231	CbGpPWpGaD
Magnesium salicylate—PTGS1—Metabolism—AKT1—thyroid cancer	9.65e-06	0.000215	CbGpPWpGaD
Magnesium salicylate—PTGS2—Disease—AKT1—thyroid cancer	9.15e-06	0.000204	CbGpPWpGaD
Magnesium salicylate—PTGS2—Metabolism—AKT1—thyroid cancer	7.66e-06	0.000171	CbGpPWpGaD
Magnesium salicylate—ALB—Metabolism—AKT1—thyroid cancer	6.2e-06	0.000138	CbGpPWpGaD
